https://www.selleckchem.com/products/vh298.html
However, more and better evidence is still needed before a definite conclusion could be drawn. Anakinra (Kineret®), an IL-1 receptor antagonist, is the first FDA-approved biologic drug for antagonizing IL-1 in patients with Rheumatoid arthritis. The less expensive production of this drug might help reduce the final therapeutic costs. To evaluate the possibility of producing biologically active recombinant IL-1Ra by a single-step purification procedure mediated by a self-cleavable intein. Soluble expression of the rIL-1Ra was performed in